Corcept - CORT Quarterly EPS earnings growth

Corcept Therapeutics Corp - graphic logo of issuer CORT

The quarterly EPS history on the current GURU.Markets platform chart demonstrates profit dynamics, where the value 525.70 represents the most recent figure. Corcept Therapeutics (CORT) benefits from the monopoly status of orphan drugs, which guarantees absolute patient loyalty. High margins are sustained through production outsourcing and a strategic focus on mifepristone. To advance endocrinology, Corcept Therapeutics (CORT) is implementing innovations for the therapy of oncology and other severe pathologies.

Corcept Therapeutics Incorporated (CORT) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Corcept Therapeutics (CORT)

- share price and consensus valuation forecast:
Stock Quotes Corcept Therapeutics Incorporated|CORT - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Corcept Therapeutics Corp|CORT - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Corcept Therapeutics|CORT - Company Book Value|Market Value to Book Value Ratio corcept.com|CORT - Company Assets
- debt and liquidity data:
Debt to Equity Corcept Therapeutics|CORT - Long-Term Debt to Equity|Short-Term Debt to Capital Corcept Therapeutics Inc.|CORT - Company Total Debt Obligations|Debt to Book Capitalization Ratio Corcept Therapeutics Inc.|CORT - Long-Term Debt Volume|Company Short-Term Debt Corcept Therapeutics|Quick Ratio corcept.com
- earnings and valuation multiples indicators:
CORT - Net Income|Expected Profit Corcept Therapeutics|CORT - Market Cap to Earnings|Future Price to Earnings Corcept Therapeutics|CORT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Corcept Therapeutics Incorporated|CORT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Corcept Therapeutics|CORT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months corcept.com|CORT - Earnings per share trend in current year|Expected earnings per share growth for next year Corcept Therapeutics
- sales volume and revenue information:
CORT - Company Total Sales|Company Future Sales Volume Corcept|CORT - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Corcept|CORT - Revenue Change YoY (Last 12 Months)
Analysis of all company metrics:Corcept Therapeutics
Manufactured product of Corcept Therapeutics Corp

For Corcept Therapeutics (CORT), a leader in the metabolic disorder therapy niche, quarterly EPS growth serves as an indicator of the efficiency of its intellectual property monetization. This metric is calculated as the percentage change in net income per share relative to the same period last year. It reflects the business's ability to convert market advantage into actual income. The trend of this indicator allows for an assessment of margin resilience in the face of patent risks and generic expansion. Stable growth confirms the fundamental viability of the business model.

Competitors of Corcept Therapeutics (CORT)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|RYTM (Rhythm Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Akero Therapeutics|Quarterly EPS earnings growth MTSR|Year-over-year earnings per share growth for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Year-over-year earnings per share growth for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS